阿立哌唑、奥氮平、利培酮治疗儿童青少年精神分裂症的效果(1)
[摘要] 目的 探討儿童青少年精神分裂症患者行阿立哌唑、奥氮平和利培酮治疗的效果。 方法 方便选取该院于2016年6月—2017年8月期间收治的儿童青少年精神分裂症患者50例，依据用药方式的不同将其分为甲组(n=17行阿立哌唑)、乙组(n=17 行奥氮平)、丙组(n=16 行利培酮)。对比3组治疗前后PANSS分数、不良反应发生率情况和血清PRL水平。 结果 ①3组患者PANSS指标显著降低，差异有统计学意义(t=6.013 5、6.256 6、6.014 5，P<0.05)，3组治疗后的指标对比，差异无统计学意义(P>0.05);②对无法静坐、恶心呕吐、口干发汗、体重上升以及肝功能异常等不良反应发生率记录，甲组上述发生几率分别为29.4%、11.8%、5.9%、0.0%、0.0%;乙组发生几率分别为17.6%、17.6%、0.0%、23.5%、11.8%;丙组发生几率为6.3%、18.8%、0.0%、12.5%、6.3%，组间对比差异无统计学意义(Z=2.998 0、0.335 4、2.062 5、4.461 9、2.088 5，P>0.05);③甲组治疗前后PRL水平对比，差异无统计学意义(P>0.05)，乙组和丙组治疗后的PRL水平上升，3组对比差异有统计学意义(F=6.711 4，P<0.05)。3组治疗前PRL水平对比，差异无统计学意义(P>0.05)，经过为期180 d治疗后，3组PRL水平有显著差异，丙组的水平高于甲组和丙组，差异有统计学意义(P<0.05)。 结论 应用阿立哌唑、奥氮平和利培酮对青少年精神分裂症患者治疗，均能达到显著效果。
[关键词] 阿立哌唑;奥氮平;利培酮;精神分裂症
[中图分类号] R445 [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0121-03
[Abstract] Objective To investigate the effects of aripiprazole， olanzapine and risperidone in children and adolescents with schizophrenia. Methods Convenient select a total of 50 children and adolescents with schizophrenia admitted to the hospital from June 2016 to August 2017 were divided into group A (n=17 of aripiprazole) and group B (n=17 of olanzapine)， group C (n=16 of risperidone). PANSS scores， incidence of adverse reactions， and serum PRL levels were compared before and after treatment. Results 1.The PANSS index of the three groups was significantly lower (t=6.013 5， 6.256 6， 6.014 5， P<0.05). There was no statistically significant difference between the three groups(P>0.05); 2.The incidence of adverse reactions such as nausea and vomiting， dry mouth sweating， weight gain， and abnormal liver function were recorded in the group A with incidence rates of 29.4%， 11.8%， 5.9%， 0.0%， and 0.0%， respectively. The incidence of group B was 17.6%， 17.6%， 0.0%， 23.5%， 11.8%; the incidence of group C was 63%， 18.8%， 0.0%， 12.5%， 6.3%， and the comparison between groups was not statistically significant(Z=2.998 0， 0.335 4， 2.062 5， 4.461 9， 2.088 5， P>0.05); 3.There was no significant difference in PRL levels before and after treatment in group A(P>0.05). The level of PRL in group B and group C increased after treatment. The comparison between the three groups was statistically significant (F=6.711 4， P<0.05). There was no statistically significant difference in PRL levels between the three groups before treatment(P>0.05). After 180 days of treatment， there were significant differences in the levels of PRL between the three groups. The level of group C was higher than that of group A and group C， which was statistically significant(P>0.05). Conclusion Aripiprazole， olanzapine and risperidone can achieve significant effects in the treatment of adolescent schizophrenia., http://www.100md.com(殷世龙)
[关键词] 阿立哌唑;奥氮平;利培酮;精神分裂症
[中图分类号] R445 [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0121-03
[Abstract] Objective To investigate the effects of aripiprazole， olanzapine and risperidone in children and adolescents with schizophrenia. Methods Convenient select a total of 50 children and adolescents with schizophrenia admitted to the hospital from June 2016 to August 2017 were divided into group A (n=17 of aripiprazole) and group B (n=17 of olanzapine)， group C (n=16 of risperidone). PANSS scores， incidence of adverse reactions， and serum PRL levels were compared before and after treatment. Results 1.The PANSS index of the three groups was significantly lower (t=6.013 5， 6.256 6， 6.014 5， P<0.05). There was no statistically significant difference between the three groups(P>0.05); 2.The incidence of adverse reactions such as nausea and vomiting， dry mouth sweating， weight gain， and abnormal liver function were recorded in the group A with incidence rates of 29.4%， 11.8%， 5.9%， 0.0%， and 0.0%， respectively. The incidence of group B was 17.6%， 17.6%， 0.0%， 23.5%， 11.8%; the incidence of group C was 63%， 18.8%， 0.0%， 12.5%， 6.3%， and the comparison between groups was not statistically significant(Z=2.998 0， 0.335 4， 2.062 5， 4.461 9， 2.088 5， P>0.05); 3.There was no significant difference in PRL levels before and after treatment in group A(P>0.05). The level of PRL in group B and group C increased after treatment. The comparison between the three groups was statistically significant (F=6.711 4， P<0.05). There was no statistically significant difference in PRL levels between the three groups before treatment(P>0.05). After 180 days of treatment， there were significant differences in the levels of PRL between the three groups. The level of group C was higher than that of group A and group C， which was statistically significant(P>0.05). Conclusion Aripiprazole， olanzapine and risperidone can achieve significant effects in the treatment of adolescent schizophrenia., http://www.100md.com(殷世龙)